X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Allerject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: KALEO INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 02, 2022
Details:
The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Desjardins Capital Markets
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 24, 2021
Details:
Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Group Purchasing Organizations
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2021
Details:
Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair® Breezhaler® and Atectura® Breezhaler® for an initial 8 year period.
Lead Product(s): Indacaterol Acetate,Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Atectura Breezhaler
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2021
Details:
Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients.
Lead Product(s): Hesperidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Hesperco
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ingenew Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Valeo Pharma has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market.
Lead Product(s): Amikacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Valeo Pharma has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Lead Product(s): Hesperidin
Therapeutic Area: Infections and Infectious Diseases Product Name: HesperCo
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Valeo Pharm has entered into a licensing agreement with Alliance Pharma plc for the exclusive commercialization rights to AmetopTM Gel (Tetracaine hydrochloride gel) in Canada.
Lead Product(s): Tetracaine Hydrochloride
Therapeutic Area: Neurology Product Name: Ametop
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Alliance Pharmaceutical Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
